Chang-Cheng Sheng

Chang-Cheng Sheng

Auto-generated profile, based on publicly available information

Chang-Cheng Sheng

Department of Pharmacy, Guizhou Provincial People’s Hospital, Guiyang, 550002, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
XYXuben Yu
Xuben Yu
Zheng JiaoZheng Jiao
Zheng Jiao
CZChun‐Hong Zhang
Chun‐Hong Zhang
YDYing Dai
Ying Dai
ZZZi‐Ye Zhou
Zi‐Ye Zhou
JPJing‐Ye Pan
Jing‐Ye Pan

29 December 2018 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
HZHuan‐Xi Zhang
Huan‐Xi Zhang
CSChang‐Cheng Sheng
Chang‐Cheng Sheng
LLLong‐Shan Liu
Long‐Shan Liu
BLBi Luo
Bi Luo
QFQian Fu
Qian Fu
CWChangxi Wang
Changxi Wang

5 November 2020 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
CWChenyu Wang
Chenyu Wang
CSChang-Cheng Sheng
Chang-Cheng Sheng
GMGuang-Li Ma
Guang-Li Ma
DXDa Xu
Da Xu
XLXiao-Qin Liu
Xiao-Qin Liu
Zheng JiaoZheng Jiao
Zheng Jiao


2 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
CWChenyu Wang
Chenyu Wang
CSChang-Cheng Sheng
Chang-Cheng Sheng
GMGuang-Li Ma
Guang-Li Ma
DXDa Xu
Da Xu
XLXiao-qin Liu
Xiao-qin Liu
Zheng JiaoZheng Jiao
Zheng Jiao
Objective: Camrelizumab, a programmed cell death 1 (PD-1) inhibitor, has been approved for the treatment of relapsed or refractory classical Hodgkin lymphoma. The aim of this study was to perform a population pharmacokinetics (PK) analysis of camrelizumab to quantify the impact of patient characteristics on PK and to investigate the appropriateness of flat dose in the dosing regimen. Methods: A total of 3298 camrelizumab concentrations from 133 patients from four studies were analyzed using nonlinear mixed effects modeling. Covariate model building was conducted using stepwise forward addition and backward elimination. Monte Carlo simulation was conducted to compare exposures of 200 mg and 3 mg/kg every 2-week regimens. Results: The PK of camrelizumab were adequately described by a two-compartment model with parallel linear and nonlinear clearances. Baseline albumin had significant effects on linear clearance, and weight had effects on inter-compartmental clearance. Moreover, 200 mg and 3 mg/kg regimens provide similar exposure distributions with no advantage to either dosing approach. Conclusion: Population PK analysis provided an integrated evaluation of the impact of albumin and weight on the PK of camrelizumab. It also provided evidence that neither the flat-dose nor the weight-based dose regimen was advantageous over the other for most patients with tumors.